Naranjo Muñoz, JavierGarcia Garcia-Doncel, AnaMontero Escobar, María ElisaVillanego Fernandez, FlorentinoMillán Ortega, IreneCeballos Guerrero, Manuel2023-01-252023-01-252019-02-21http://hdl.handle.net/10668/13621enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/AdultAntibodies, Monoclonal, HumanizedAtypical Hemolytic Uremic SyndromeComplement Inactivating AgentsHumansMaleTime FactorsEculizumab for atypical hemolytic-uremic syndrome. How long should we maintain it?Eculizumab en el síndrome hemolítico urémico atípico. ¿Hasta cuándo mantenerlo?research article30798995open access10.1016/j.nefro.2019.01.0012013-2514https://doi.org/10.1016/j.nefro.2019.01.001